In Vitro Evaluation of PARP1 Inhibitor Olaparib‐Cyanine Dye Conjugate for the Treatment of Glioblastoma
ChemMedChem · 2026-04-28 · 21 (8)
DOI: 10.1002/cmdc.70286 ↗At a glance
Journal article in ChemMedChem, published online on 2026-04-25. Written by Carina Dumo and 8 co-authors. Institution: Auckland Cancer Society Research Centre, School of Medical Sciences, University of Auckland, Auckland, New Zealand. Major MEDLINE topics: Phthalazines, Piperazines, Poly(ADP-ribose) Polymerase Inhibitors, Antineoplastic Agents. 45 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: NIGMS NIH HHS, NIH HHS, Cure Kids.
Abstract (original language)
Inhibition of DNA damage repair is a common mechanism to induce cancer cell death and, therefore, to treat cancers such as breast, prostate and ovarian cancer. This approach, although very attractive, has not been feasible for treating brain tumours due to the stringent structural features necessary for pharmaceutical agents to cross the blood–brain barrier (BBB). This study presents the proof of concept in vitro cellular activity of PARP1 (Poly(ADP‐ribose) polymerase 1) enzyme inhibitor olaparib conjugated with a known BBB‐crossing heptamethine cyanine dye. We also present evidence for cellular uptake and PARP1 inhibition by the conjugate, which contributes to the observed improvement in potency.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Auckland Cancer Society Research Centre, School of Medical Sciences, University of Auckland, Auckland, New Zealand.
- Department of Pharmacology & The Centre for Brain Research, University of Auckland, Auckland, New Zealand.
- Neurosurgical Research Unit, The Centre for Brain Research, University of Auckland, Auckland, New Zealand.
- Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Auckland, New Zealand.
- Department of Medicinal Chemistry, University of Utah, Salt Lake City, Utah, USA.
ORCID profiles: Faheem, Jiney Jose
Funding
- NIGMS NIH HHS
- NIH HHS
- Cure Kids
- Neurological Foundation of New Zealand
- Child Health Research Foundation
- US National Institutes of Health
Cite
APA
Dumo, C., Faheem, Choi, P. J., Pederson, N. J., Liu, Y., Dragunow, M., Park, T. I., Diehl, K. L., & Jose, J. (2026). In Vitro Evaluation of PARP1 Inhibitor Olaparib‐Cyanine Dye Conjugate for the Treatment of Glioblastoma. ChemMedChem, 21(8). https://doi.org/10.1002/cmdc.70286
Vancouver
Dumo C, Faheem, Choi PJ, Pederson NJ, Liu Y, Dragunow M, et al. In Vitro Evaluation of PARP1 Inhibitor Olaparib‐Cyanine Dye Conjugate for the Treatment of Glioblastoma. ChemMedChem. 2026;21(8). doi:10.1002/cmdc.70286
BibTeX
@article{Dumo2026,
author = {Dumo, Carina and Faheem and Choi, Peter J and Pederson, Nicholas J and Liu, Yuge and Dragunow, Mike and Park, Thomas I-H and Diehl, Katharine L and Jose, Jiney},
title = {In Vitro Evaluation of PARP1 Inhibitor Olaparib‐Cyanine Dye Conjugate for the Treatment of Glioblastoma},
journal = {ChemMedChem},
year = {2026},
volume = {21},
number = {8},
doi = {10.1002/cmdc.70286}
}
EUVIMED